Shares of Tesaro Inc. (NASDAQ:TSRO) were down 1.7% during mid-day trading on Tuesday . The stock traded as low as $88.17 and last traded at $89.51, with a volume of 380,420 shares traded. The stock had previously closed at $91.02.

Several analysts recently issued reports on TSRO shares. FBR & Co started coverage on Tesaro in a research report on Wednesday, April 13th. They set an “outperform” rating and a $65.00 target price for the company. Zacks Investment Research upgraded Tesaro from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Mizuho restated a “buy” rating and set a $67.00 price target on shares of Tesaro in a report on Wednesday, April 6th. Wells Fargo & Co. restated an “outperform” rating on shares of Tesaro in a report on Thursday, June 30th. Finally, Jefferies Group cut Tesaro from a “buy” rating to a “hold” rating and raised their price target for the company from $53.00 to $75.00 in a report on Thursday, June 30th. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $76.50.

The stock has a 50 day moving average price of $66.79 and a 200 day moving average price of $48.06. The firm’s market capitalization is $4.13 billion.

Tesaro (NASDAQ:TSRO) last released its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.69) by $0.53. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $2.48 million. During the same period in the prior year, the firm earned ($1.30) earnings per share. On average, equities research analysts anticipate that Tesaro Inc. will post ($7.16) earnings per share for the current fiscal year.

In other news, VP Edward C. English sold 7,000 shares of the business’s stock in a transaction on Friday, June 10th. The shares were sold at an average price of $40.75, for a total transaction of $285,250.00. Following the completion of the sale, the vice president now directly owns 3,500 shares of the company’s stock, valued at approximately $142,625. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Jeffrey H. Hanke sold 12,500 shares of the business’s stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the sale, the vice president now directly owns 12,500 shares of the company’s stock, valued at $929,375. The disclosure for this sale can be found here.

Several hedge funds recently made changes to their positions in TSRO. Nationwide Fund Advisors boosted its stake in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 330 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of Tesaro by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,152 shares of the biopharmaceutical company’s stock valued at $2,258,000 after buying an additional 752 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares in the last quarter. ProShare Advisors LLC bought a new stake in shares of Tesaro during the fourth quarter valued at about $1,864,000. Finally, Mutual of America Capital Management LLC boosted its stake in shares of Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock valued at $2,068,000 after buying an additional 19,320 shares in the last quarter.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.